Hepatitis B viral assembly effectors
US9796722B1 · kind B1 · utility
3Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 14, 2016 |
| Grant date | Oct 24, 2017 |
| Priority date | — |
| Expiry date | Oct 14, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Novel virus assembly effector compounds having a therapeutic effect against Hepatitis B viral infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed are pharmaceutical compositions including the disclosed compounds, methods of treatment of HBV infection, and a process to synthesize the disclosed compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.